BioNexus Gene Lab Corp Common stock - Asset Resilience Ratio
BioNexus Gene Lab Corp Common stock (BGLC) has an Asset Resilience Ratio of 22.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of BioNexus Gene Lab Corp Common stock for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how BioNexus Gene Lab Corp Common stock's Asset Resilience Ratio has changed over time. See BGLC net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BioNexus Gene Lab Corp Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of BioNexus Gene Lab Corp Common stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.74 Million | 22.85% |
| Total Liquid Assets | $1.74 Million | 22.85% |
Asset Resilience Insights
- Good Liquidity Position: BioNexus Gene Lab Corp Common stock maintains a healthy 22.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
BioNexus Gene Lab Corp Common stock Industry Peers by Asset Resilience Ratio
Compare BioNexus Gene Lab Corp Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 2.16% |
|
Air Products and Chemicals Inc
NYSE:APD |
Specialty Chemicals | 2.49% |
|
Akzo Nobel NV
AS:AKZA |
Specialty Chemicals | 2.16% |
|
Swancor Advanced Materials Co Ltd
SHG:688585 |
Specialty Chemicals | 11.19% |
|
Azelis Group NV
BR:AZE |
Specialty Chemicals | 0.00% |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576 |
Specialty Chemicals | 9.08% |
|
Jihua Group Corp Ltd
SHG:601718 |
Specialty Chemicals | 0.00% |
|
Jiangxi Guotai Civilian
SHG:603977 |
Specialty Chemicals | 12.39% |
Annual Asset Resilience Ratio for BioNexus Gene Lab Corp Common stock (2017–2024)
The table below shows the annual Asset Resilience Ratio data for BioNexus Gene Lab Corp Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.78% | $2.79 Million | $10.43 Million | -2.22pp |
| 2023-12-31 | 29.00% | $3.31 Million | $11.40 Million | +11.75pp |
| 2022-12-31 | 17.24% | $1.51 Million | $8.74 Million | +1.10pp |
| 2021-12-31 | 16.14% | $1.55 Million | $9.57 Million | -4.50pp |
| 2020-12-31 | 20.64% | $2.09 Million | $10.12 Million | -19.40pp |
| 2019-12-31 | 40.04% | $493.04K | $1.23 Million | +3.67pp |
| 2018-12-31 | 36.38% | $601.00K | $1.65 Million | +36.18pp |
| 2017-12-31 | 0.20% | $2.55K | $1.27 Million | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more